Sanofi Lifts Forecast as Vaccines, Eczema Drug Provide Fuel

(Bloomberg) -- Sanofi modestly boosted its 2018 outlook after reporting its first quarterly earnings increase in more than a year, showing that the company’s strategy may be moving in the right direction again. The shares surged the most in two years.

• Earnings per share will rise 4 percent to 5 percent this year. The low end of the range is 1 percentage point higher than Sanofi’s previous forecast. Sanofi’s third-quarter earnings -- the first gain since the second quarter of last year -- beat analyst estimates.

Key Insights

• The results show that a drug Sanofi is relying on as a key driver -- Dupixent, for a severe form of eczema -- is living up to its promise with sales of 225 million euros ($255 million), slightly ahead of analysts’ estimates.
• The company needs new products because older stalwarts are slumping: Diabetes treatment Lantus plunged 18 percent in the quarter amid fierce competition in the U.S. Sanofi is counting on $16 billion of takeovers, including its purchase of Bioverativ, to help spur growth.
• Sanofi is also getting a lift from its vaccine business, whose sales are now projected to grow in the mid- to high-single-digit range in the second half, slightly better than previous forecasts, the new finance chief, Jean-Baptiste Chasseloup de Chatillon, told reporters on a call.

Market Reaction

• Sanofi gained as much as 5.1 percent, the most most since November 2016, in early trading in Paris.

Get More

• For more details, click here.

To contact the reporter on this story: James Paton in London at jpaton4@bloomberg.net

To contact the editors responsible for this story: Eric Pfanner at epfanner1@bloomberg.net, John Lauerman

©2018 Bloomberg L.P.